Oxford BioTherapeutics

OverviewSuggest Edit

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

HQMilton, GB

Latest Updates

Employees (est.) (Apr 2022)30(+4%)
Revenue (FY, 2018)£2.1 M(-54%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oxford BioTherapeutics

Jean-Pierre Bizzari

Jean-Pierre Bizzari

Non-Executive Director
Fiona Irvine

Fiona Irvine

Vp & Head of Human Resources
John McHutchison

John McHutchison

Non-Executive Director
Abderrahim Fandi

Abderrahim Fandi

Chief Medical Officer
Ken Sayre

Ken Sayre

Vp Finance & Us Operations
Jason Gould

Jason Gould

Non-Executive Director
Show more

Oxford BioTherapeutics Office Locations

Oxford BioTherapeutics has offices in Milton and San Jose
Milton, GB (HQ)
94a Innovation Dr
San Jose, CA, US
5941 Optical Ct
Show all (2)

Oxford BioTherapeutics Financials and Metrics

Summary Metrics

Founding Date


Oxford BioTherapeutics total Funding

$21.6 m

Oxford BioTherapeutics latest funding size

$10 m

Time since last funding

7 years ago

Oxford BioTherapeutics investors

Oxford BioTherapeutics's latest funding round in July 2015 was reported to be $10 m. In total, Oxford BioTherapeutics has raised $21.6 m
Show all financial metrics

Oxford BioTherapeutics Revenue

Oxford BioTherapeutics's revenue was reported to be £2.09 m in FY, 2018

Revenue (FY, 2018)


Net income (FY, 2018)


EBIT (FY, 2018)


Cash (31-Dec-2018)

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017FY, 2018



Cost of goods sold


Gross profit


Gross profit Margin, %

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017

Net Income


Income Taxes Paid

GBPFY, 2004

Financial Leverage

7.6 x
Show all financial metrics

Oxford BioTherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Oxford BioTherapeutics Online and Social Media Presence

Embed Graph

Oxford BioTherapeutics News and Updates

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

OXFORD, England and SAN JOSE, Calif., April 13, 2022 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised its option to...

Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics

Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billi…

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076

OXFORD, England and SAN JOSE, Calif., December 21, 2018 /PRNewswire/ -- An experimental first in class ADC medicine for high risk Her2 negative breast cancer, gastric, lung, bladder and ovarian cancer patients - US phase I clinical trial to be initiated. Oxford BioTherapeutics Ltd....

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kindom, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"),...

Oxford BioTherapeutics Frequently Asked Questions

  • When was Oxford BioTherapeutics founded?

    Oxford BioTherapeutics was founded in 2004.

  • Who are Oxford BioTherapeutics key executives?

    Oxford BioTherapeutics's key executives are Jean-Pierre Bizzari, Fiona Irvine and John McHutchison.

  • How many employees does Oxford BioTherapeutics have?

    Oxford BioTherapeutics has 31 employees.

  • What is Oxford BioTherapeutics revenue?

    Latest Oxford BioTherapeutics annual revenue is £2.1 m.

  • What is Oxford BioTherapeutics revenue per employee?

    Latest Oxford BioTherapeutics revenue per employee is £67.4 k.

  • Who are Oxford BioTherapeutics competitors?

    Competitors of Oxford BioTherapeutics include Ajinomoto Bio-Pharma Services, Adverum Biotechnologies and UniQure.

  • Where is Oxford BioTherapeutics headquarters?

    Oxford BioTherapeutics headquarters is located at 94a Innovation Dr, Milton.

  • Where are Oxford BioTherapeutics offices?

    Oxford BioTherapeutics has offices in Milton and San Jose.

  • How many offices does Oxford BioTherapeutics have?

    Oxford BioTherapeutics has 2 offices.